Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We will conduct a systematic review and meta-analysis on the comparison of the efficacy of immunotherapy (PD1 and PDL1 inhibitors) alone and traditional platinum-based chemotherapy, so as to provide a reliable basis for clinicians to formulate the best chemotherapy regimen for patients with esophageal cancer after esophagectomy.
|
31096448 |
2019 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, we explored the mechanism and found that calcineurin-nuclear factor of activated T cells 3 (NFATc3) pathway contributed to the expression of programmed death ligand 1 (PD-L1) induced by TRPM8 overexpression and TRPM8 agonist, which might lead to immune evasion of esophageal cancer cells.
|
31519770 |
2019 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, previous studies reported that the expression of programmed death-ligand 1 is significantly associated with esophageal cancer prognosis.
|
31612012 |
2019 |
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PD-L1 expression was associated with an unfavorable clinical outcome in esophageal cancer, supporting its role as a prognostic biomarker.
|
29206673 |
2019 |
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Soluble PD-L1, PD-1, CD155, LAG3, and CD226 (sPD-L1, sPD-1, sCD155, sLAG3, and sCD226, respectively) were measured in the sera of 47 patients with advanced esophageal cancer and compared with those of 24 control subjects.
|
31134385 |
2019 |
Esophageal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Checkpoint inhibitors, specifically the anti-PD-1/PD-L1 inhibitors, seem to be beneficial for a subgroup of patients with advanced gastric or esophageal cancer who have progressed on multiple systemic chemotherapies.
|
30275174 |
2018 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 expression in tumor cells detected by IHC was associated with worse OS in EC.
|
30045299 |
2018 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study sought to evaluate the effect of tumor-infiltrating lymphocyte (TIL) density and programmed death ligand 1 (PD-L1) expression on the prognosis of esophageal cancer.
|
29859152 |
2018 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Available reports regarding PD-1, PD-L1, PD-L2 expression and MSI status in gastric and esophageal cancer are reviewed to summarize the clinical prognostic and predictive role together with potential clinical implications.
|
30577521 |
2018 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Results Among 83 patients with esophageal carcinoma and samples evaluable for PD-L1 expression, 37 (45%) had PD-L1-positive tumors, and 23 were enrolled.
|
29116900 |
2018 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 was overexpressed in EC compared with normal esophageal epithelium, with a positive expression rate of 37.5%.
|
29552135 |
2018 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of the programmed death ligand-1 (PD-L1) was reported but the clinical relevance remained inconsistent in esophageal cancer.
|
30174892 |
2018 |
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that simultaneous inhibition of IDO1 and PD-(L)1 may overcome important barriers to T-cell mediated immune rejection of EC.
|
29805749 |
2018 |
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical significance of molecules related immune checkpoints, especially PD-1 and PD-L1 is presented and the designs, results and future directions of clinical trials using immunotherapy in EC are provided.
|
28366014 |
2017 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The purpose of the present study was to investigate the association between MutL homolog 1 (MLH1) expression and prognosis, response to therapy and PD-L1 expression in esophageal cancer.
|
28693258 |
2017 |
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analyzing a panel of biomarkers including those affiliated with taxane and platinum resistance (ERCC1 and TUBB3) as well as immunotherapy effectiveness (PD-L1) would provide oncologists more information on how to optimize first-line therapy for EC.
|
27838937 |
2017 |
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy.
|
28314315 |
2017 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, PD-L1 IHC expression was significantly correlated with worse overall survival rates in patients with esophageal cancer and renal cell carcinoma and with worse disease-free survival rates in patients with colorectal cancer, hepatocellular carcinoma, and renal cell carcinoma.
|
27470134 |
2017 |
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, our study also indicated that PD-1 fusion protein mediated stimulation of PD-L1 and the cytoplasmic domain of PD-L1 played a critical role in promoting EMT phenotype of Eca-109 cells, thereby suggesting that PD-1 receptor usually by triggering the reverse signaling can effect PD-L1 mediated regulation of esophageal cancer cell response.
|
28848143 |
2017 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the expression of PD-L1 and PD-L2 in human esophageal cancer to define their clinical significance in patients' prognosis after surgery.
|
15837746 |
2005 |